Comparative Pharmacology
Head-to-head clinical analysis: ACUVUE THERAVISION WITH KETOTIFEN versus DISOMER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ACUVUE THERAVISION WITH KETOTIFEN versus DISOMER.
ACUVUE THERAVISION WITH KETOTIFEN vs DISOMER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ketotifen is a selective histamine H1-receptor antagonist and mast cell stabilizer that inhibits the release of inflammatory mediators such as histamine and leukotrienes from mast cells.
Selective dopamine D2 receptor antagonist; also blocks alpha-1 adrenergic, histamine H1, and muscarinic M1 receptors.
One drop in each affected eye twice daily (approximately 8 hours apart) as needed. The lens should be removed prior to instillation and can be reinserted after at least 10 minutes.
Adults: 1 mg orally once daily.
None Documented
None Documented
12 hours (terminal elimination half-life; clinical context: twice-daily dosing needed for continuous effect).
12–15 hours in adults with normal renal function; prolonged to 30–40 hours in severe renal impairment (CrCl <30 mL/min).
Renal (approximately 50% as unchanged drug, 30% as metabolites); biliary/fecal elimination accounts for <10%.
Renal: 80% as unchanged drug; biliary/fecal: 15% as metabolites; <5% unchanged in feces.
Category A/B
Category C
Antihistamine / Mast Cell Stabilizer
Antihistamine